Market
How many types of cancer will be treatable with Flash Radiotherapy by the end of 2027?
2
Resolution / Starting Odds
Less than 5 • 25%
5 to 10 • 25%
11 to 20 • 25%
More than 20 • 25%
Peer-reviewed medical journals or clinical guidelines
Story
New Ultra-Fast Cancer Treatment ErSO-TFPy Promises Less Side Effects and Rapid Results in Less Than a Second
Jan 23, 2025, 03:02 AM
Recent research highlights a groundbreaking ultra-fast cancer treatment that could potentially replace conventional radiotherapy. This innovative approach, referred to as Flash Radiotherapy, promises to address a broader range of cancers while minimizing side effects and significantly reducing treatment time to less than a second. Additionally, a study on the drug candidate ErSO-TFPy has demonstrated its effectiveness in eradicating small breast cancer tumors in mice, indicating potential for treating estrogen receptor-positive breast cancer with minimal side effects. Further testing is required to confirm these findings and assess the treatments' applicability in clinical settings.
View original story
Similar markets
More than 80% • 25%
75% to 80% • 25%
50% to 74% • 25%
Less than 50% • 25%
1,000 to 5,000 • 25%
Less than 1,000 • 25%
More than 10,000 • 25%
5,001 to 10,000 • 25%
1 • 25%
2 • 25%
None • 25%
3 or more • 25%
More than 10 countries • 25%
1 to 5 countries • 25%
No countries • 25%
6 to 10 countries • 25%
50,001 to 100,000 • 25%
Less than 10,000 • 25%
10,000 to 50,000 • 25%
More than 100,000 • 25%
Less than 10,000 • 25%
More than 100,000 • 25%
50,001 to 100,000 • 25%
10,000 to 50,000 • 25%
Less than 10,000 • 25%
More than 100,000 • 25%
50,001 to 100,000 • 25%
10,000 to 50,000 • 25%
Other • 25%
Roche • 25%
Johnson & Johnson • 25%
AstraZeneca • 25%
Prostate cancer • 25%
Other types • 25%
Lung cancer • 25%
Breast cancer • 25%
Other • 25%
Colon Cancer • 25%
Breast Cancer • 25%
Lung Cancer • 25%
One • 25%
Three or more • 25%
None • 25%
Two • 25%
More than 100,000 • 25%
50,001 to 100,000 • 25%
10,000 to 50,000 • 25%
Less than 10,000 • 25%